CEO Admits to Embarrassing Lie That Involves Army, Puts Hope in Clinical Trial Progress.
of them being still active on the trial at the time of the presentation. The enrollment of the randomized open label Phase II FORTIS trial has successfully been completed. The trial evaluates iadademstat as a monotherapy in relapsed/refractory myelodysplastic syndrome (MDS) patients who are unresponsive or intolerant to standard of care hypomethylating agents. Enrollment of the 50 patient cohort was completed in December 2022.
Original Release: https://www.globenewswire.com/news-release/2023/02/17/2610827/0/en/ORYZON-Reports-Financial-Results-and-Corporate-Update-for-Quarter-Ended-December-31-2022.html